PROG Holdings, Inc.: valuation
Price
$38.38
November 13, 2026Market cap $1.5B
What Ploutos Investor adds for PROG
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 24% since Oct 28, 2026, when the 10-Q these figures come from was filed ($30.88 then, $38.38 on Nov 13, 2026). The figures date from before that move.10-Q
Valuation today
What the market pays for the company's earnings, cash flow, book value and revenue at $38.38 (November 13, 2026), beside the median of its past fiscal years.
Today's P/E (10.1) is 8% above the median of the chart's 3 years (9.3).
- EV / EBIT
- 9.7
- EV / Revenue
- 0.8
- Earnings yield
- 9.9%
- FCF yield
- 20.8%
- Market cap
- $1.5B
- enterprise value $2.3B
- 2025P/E8.2
- 2024P/E9.3
- 2023P/E10.4
| Year | Price | P/E | P/FCF | P/B | P/S |
|---|---|---|---|---|---|
| 2025 | $29.49 | 8.2 | 3.6 | 1.6 | 0.5 |
| 2024 | $42.26 | 9.3 | 13.2 | 2.7 | 0.7 |
| 2023 | $30.91 | 10.4 | 6.9 | 2.3 | 0.6 |
Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF.
Valuation against its own past
PRG's P/E, P/FCF and P/B at each year-end price, from 2018 to 2022, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
What today's price assumes
The discounted cash flow model run backwards: not what the company is worth, but the growth the price takes for granted.
For a buyer at $38.38 who wants 9% a year, free cash flow would need to grow by about
-8.8%a year for ten years
Over the last 5 years it grew by -3.7% a year.
- at 7% a year
- -12.4%
- at 9% a year
- -8.8%
- at 11% a year
- -5.8%
Arithmetic on the price, not a forecast. Starts from free cash flow of $316M over the last 12 months and net debt $757M, the same growth each year for ten years, then 2.5% a year forever. Try other numbers in the DCF calculator.
DCF calculator
What is PROG worth on your own assumptions?
The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.
- Free cash flow, 12 months
- $316M
- Net debt
- $757M
- Shares
- 39.58M
- FCF, 5-year average a year
- -3.7%
- Revenue, 5-year average a year
- -0.6%
- Price
- $38.38
The full analysis
What do PROG's filings show?
The multiples say what the market pays for PROG. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is PRG's P/E?
PRG's P/E is 10.1, on earnings per share of $3.70 over the last 12 months. The median over the last 5 fiscal years was 9.3.
What is PRG's P/FCF?
PRG's P/FCF is 4.8: a market cap of $1.5B over $316M of free cash flow in the last 12 months. Put the other way, a free cash flow yield of 20.8%.
How do I work out what PRG is worth?
With the DCF calculator: it opens with PROG's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.